Journal of Gastrointestinal Surgery

, Volume 14, Issue 2, pp 211–220 | Cite as

Duodenal Switch Provides Superior Resolution of Metabolic Comorbidities Independent of Weight Loss in the Super-obese (BMI ≥ 50 kg/m2) Compared with Gastric Bypass

  • Vivek N. Prachand
  • Marc Ward
  • John C. Alverdy
2009 SSAT Plenary Presentation



Increased body mass index is associated with greater incidence and severity of obesity-related comorbidities and inadequate postbariatric surgery weight loss. Accordingly, comorbidity resolution is an important measure of surgical outcome in super-obese individuals. We previously reported superior weight loss in super-obese patients following duodenal switch (DS) compared to Roux-en-Y gastric bypass (RYGB) in a large single institution series. We now report follow-up comparison of comorbidity resolution and correlation with weight loss.


Data from patients undergoing DS and RYGB between August 2002 and October 2005 were prospectively collected and used to identify super-obese patients with diabetes, hypertension, dyslipidemia, and gastroesophageal reflux disease (GERD). Ali–Wolfe scoring was used to describe comorbidity severity. Chi-square analysis was used to compare resolution and two-sample t tests used to compare weight loss between patients whose comorbidities resolved and persisted.


Three hundred fifty super-obese patients [DS (n = 198), RYGB (n = 152)] were identified. Incidence and severity of hypertension, dyslipidemia, and GERD was comparable in both groups while diabetes was less common but more severe in the DS group (24.2% vs. 35.5%, Ali–Wolfe 3.27 vs. 2.94, p < 0.05). Diabetes, hypertension, and dyslipidemia resolution was greater at 36 months for DS (diabetes, 100% vs. 60%; hypertension, 68.0% vs. 38.6%; dyslipidemia, 72% vs. 26.3%), while GERD resolution was greater for RYGB (76.9% vs. 48.57%; p < 0.05). There were no differences in weight loss between comorbidity “resolvers” and “persisters”.


In comparison to RYGB, DS provides superior resolution of diabetes, hypertension, and dyslipidemia in the super-obese independent of weight loss.


Morbid obesity Super-obesity Comorbidity resolution Duodenal switch Gastric bypass Bariatric surgery Diabetes Gastroesophageal reflux Biliopancreatic diversion 



We would like acknowledge Shang Lin, Ph.D. for his assistance with the statistical analysis and Roy T. DaVee for database assistance.


  1. 1.
    Flegal KM, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.CrossRefPubMedGoogle Scholar
  2. 2.
    Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295:1549–1555.CrossRefPubMedGoogle Scholar
  3. 3.
    Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health 2007;121(7):492–496.CrossRefPubMedGoogle Scholar
  4. 4.
    Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083–1096.CrossRefGoogle Scholar
  5. 5.
    Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007;61(5):737–747.CrossRefPubMedGoogle Scholar
  6. 6.
    Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008;207:928–934.CrossRefPubMedGoogle Scholar
  7. 7.
    LABS Writing Group. Relationship of body mass index with demographic and clinical characteristics in the Longitudinal Assessment of Bariatric Surgery (LABS). SOARD 2008;4(4):474–480.Google Scholar
  8. 8.
    Gregg EW, Cheng YJ, Cadwell BL et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293(15):1868–1874.CrossRefPubMedGoogle Scholar
  9. 9.
    Alley DE, Chang VW. The changing relationship of obesity and disability, 1988–2004. JAMA 2007;298(17):2020–2027.CrossRefPubMedGoogle Scholar
  10. 10.
    Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547–559.PubMedGoogle Scholar
  11. 11.
    National Institutes of Health Consensus Development Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991;115:956–961.Google Scholar
  12. 12.
    Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.CrossRefPubMedGoogle Scholar
  13. 13.
    Clegg AJ, Colquitt J, Sidhu MK et al. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6:1–153.PubMedGoogle Scholar
  14. 14.
    Mason EE, Doherty C, Maher JW et al. Super obesity and gastric reduction procedures. Gastroenterol Clin North Am 1987;6:495–502.Google Scholar
  15. 15.
    Artuso D, Wayne M, Kaul A et al. Extremely high body mass index is not a contraindication to laparoscopic gastric bypass. Obes Surg 2004;6:750–754.CrossRefGoogle Scholar
  16. 16.
    Bloosmston M, Zervos EE, Camps MA et al. Outcome following bariatric surgery in super versus morbidly obese patients: does weight matter? Obes Surg 1997;7:414–419.CrossRefGoogle Scholar
  17. 17.
    MacLean LD, Rhode B, Nohn CW. Late outcome of isolated gastric bypass. Ann Surg 2000;231:524–528.CrossRefPubMedGoogle Scholar
  18. 18.
    Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg 2008;12(2):250–255.CrossRefPubMedGoogle Scholar
  19. 19.
    Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998;8:267–282.CrossRefPubMedGoogle Scholar
  20. 20.
    Marceau P, Biron S, Bourque RA et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg 1993;3:29–35.CrossRefPubMedGoogle Scholar
  21. 21.
    Marceau P, Hould FS, Simard S et al. Biliopancreatic diversion with duodenal switch. World J Surg 1998;22:947–954.CrossRefPubMedGoogle Scholar
  22. 22.
    DeMeester TR, Fuchs KH, Ball CS et al. Experimental and clinical results with proximal end-to-end duodenojejunostomy for pathologic duodenogastric reflux. Ann Surg 1987;206:414–426.CrossRefPubMedGoogle Scholar
  23. 23.
    Scopinaro N, Gianetta E, Civalleri D et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg 1979;66:618–620.CrossRefPubMedGoogle Scholar
  24. 24.
    Fazylov RM, Savel RH, Horovitz JH et al. Association of super-superobesity and male gender with elevated mortality in patients undergoing the duodenal switch procedure. Obesity Surg 2005;15:618–623.CrossRefGoogle Scholar
  25. 25.
    Dolan K, Hatzifotis M, Newbury L et al. A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch. Ann Surg 2004;240:51–56.CrossRefPubMedGoogle Scholar
  26. 26.
    Slater GH, Ren CJ, Siegel N et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg 2004;8:48–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Prachand VN, DaVee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI ≥ 50 kg/m2) compared with gastric bypass. Ann Surg 2006;244:611–619.PubMedGoogle Scholar
  28. 28.
    Crémieux P, Buchwald H, Shikora SA et al. A study on the economic impact of bariatric surgery. Am J Manag Care 2008;14(9):589–596.PubMedGoogle Scholar
  29. 29.
    Williamson DF, Serdula MK, Anada RF, Levy A, Byers T. Weight loss attempts in adults: goals, duration, and rate of weight loss. Am J Pub Health 1992;82:1251–1257.CrossRefGoogle Scholar
  30. 30.
    NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 1998 No. 98-4083.Google Scholar
  31. 31.
    Schauer P, Ikramuddin S, Gourash W et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515–529.CrossRefPubMedGoogle Scholar
  32. 32.
    Hess DS, Hess DW, Oakley RS. The biliopancreatic diversion with the duodenal switch: results beyond 10 years. Obes Surg 2005;15:408–416.CrossRefPubMedGoogle Scholar
  33. 33.
    Anthone GJ, Lord RV, DeMeester TR et al. The duodenal switch operation for the treatment of morbid obesity. Ann Surg 2003;238:618–628.PubMedGoogle Scholar
  34. 34.
    Marceau P, Biron S, Hould FS, Lebel S, Marceau S, Lescelleur O, Biertho L, Simard S. Duodenal switch: long-term results. Obes Surg 2007;17(11):1421–1430.CrossRefPubMedGoogle Scholar
  35. 35.
    Ali MR, Maguire MB, Wolfe BM. Assessment of obesity-related comorbidities: a novel scheme for evaluating bariatric surgical patients. J Am Coll Surg 2006;202:70–77.CrossRefPubMedGoogle Scholar
  36. 36.
    Kellogg TA, Andrade R, Maddaus M, Slusarek B, Buchwald H, Ikramuddin S. Anatomic findings and outcomes after antireflux procedures in morbidly obese patients undergoing laparoscopic conversion to Roux-en-Y gastric bypass. Surg Obes Relat Dis 2007;3(1):52–57. discussion 58–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Savage AP, Adrian TE, Carolan G et al. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987;28:166–170.CrossRefPubMedGoogle Scholar
  38. 38.
    Gutzwiller JP, Goke B, Drewe J et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81–86.PubMedCrossRefGoogle Scholar
  39. 39.
    Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987;2:1300–1304.CrossRefPubMedGoogle Scholar
  40. 40.
    Morinigo R, Moize V, Musri M et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006;91:1735–1740.CrossRefPubMedGoogle Scholar
  41. 41.
    Borg CM, le Roux CW, Ghatei MA et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93:210–215.CrossRefPubMedGoogle Scholar
  42. 42.
    Clements RH, Gonzalez QH, Long CI et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004;70:1–4.PubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2009

Authors and Affiliations

  • Vivek N. Prachand
    • 1
  • Marc Ward
    • 2
  • John C. Alverdy
    • 1
  1. 1.Section of General Surgery, Department of SurgeryUniversity of Chicago Medical CenterChicagoUSA
  2. 2.Pritzker School of MedicineUniversity of ChicagoChicagoUSA

Personalised recommendations